Summary

Other Scenarios:

Buyer: Roche Holding Ltd. (ADR) (RHHBY) Last Price: 74.60 Market Cap.: 128.69B
Target: Chiron Corporation (CHIR) Last Price: 47.94 Market Cap.: 9.45B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 857
Biopharmaceuticals 314
Medical Devices 245
Outsourced Services   69
Scientific Products   43

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 237)
  • Xolair (Omalizumab)
  • Cardene (Nicardipine Hydrochloride)
  • Dilatrend (Carvedilol)
  • Bumex (Bumetanide)
Target (Total: 42)
  • Regranex (Beclapermin)
  • Betaseron (Interferon Beta-1b)
  • TOBI (Tobramycin)
  • (Tobi) Inhalable Tobramycin
Buyer
  • Roche Diagnostics AVL Compact 1-3
  • Roche Diagnostics AVL 988 Series
  • Roche Diagnostics OMNI Series
  • Roche Diagnostics AVL 9180 Series
Target
  • vCJD Immunoassay Kit
  • HTLV-III ELISA
  • HTLV-I/II ELISA
  • HBsAg System 3 ELISA

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 49)
  • Memory Pharmaceuticals Corp. (MEMY)
  • Emisphere Technologies Inc. (EMIS)
  • deCODE genetics, Inc. (DCGN)
  • Vernalis plc (ADR) (VNLS)
Target (Total: 15)
  • International Business Machines Corp. (IBM)
  • sanofi-aventis (ADR) (SNY)
  • Novartis AG (ADR) (NVS)
  • Amgen, Inc. (AMGN)
Buyer (Total: 18)
  • Laboratory Corp. of America (LH)
  • Applied Biosystems Group, Applera Corp (ABI)
  • PDL BioPharma Inc. (PDLI)
  • Gen-Probe Incorporated (GPRO)
Target (Total: 16)
  • Schering AG (ADR) (SHR)
  • Johnson & Johnson (JNJ)
  • GlaxoSmithKline plc (ADR) (GSK)
  • sanofi-aventis (ADR) (SNY)

Key Financial Summary:

Metric Buyer Target
Number of Employees 68,218 5,500
Revenue Per Employee 424,761.9 447,737.9
Total Revenue 27,655.5 614.0
Total Expenses 20,904.2 476.6
Other Revenue 0.0 15.2
Cost of Revenue 7,245.8 221.1
SG&A Expense 9,277.7 125.4
Research & Development 4,443.0 109.3
Other Operating Expense -1,126.9 7.7
Operating Income 6,751.3 137.4
Unusual Income 277.2 1.1
Gross Margin % 73.8 63.99
Metric Buyer Target
Operating Margin % 24.41 22.38
Total Assets 54,020.5 4,747.5
Return on Equity % 19.31 18.5
Cash+ ST Inv. Per Share 9.46 3.37
Total Debt 7,530.9 1,097.2
Curr Portion of LTD/Cap Lease 271.0 49.6
Total Debt to Equity 27.69 36.77
LT Debt to Capital 21.07 25.98
Fwd P/E 28.26 26.49
Fwd P/Rev 4.23 4.31
Book Value 27,196.8 2,984.1

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Biopharmaceuticals

Target

Focused (): *Healthcare > Biopharmaceuticals > Infectious Diseases

Business Description

Buyer

Roche Holding Ltd. is in the business of pharmaceuticals and diagnostics. Its pharmaceutical division offers a portfolio of medicines in various therapeutic areas, including cancer, human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS), hepatitis C, transplantation, dermatology and influenza. The Company's diagnostic division supplies an array of testing products and services to researchers, physicians, patients, hospitals and laboratories worldwide. Its products and services address prevention, diagnosis, treatment and the monitoring of diseases. The Company has operations in approximately 150 countries. During the year ended December 31, 2004, the Company has 64 new molecular entities in the research and development pipeline. In 2004, the Company's first deoxyribonucleic acid (DNA) chip-based test introduced to support more personalized therapy.

Target

Chiron Corporation is a global biopharmaceutical company. The Company operates in three healthcare three-business units: blood testing, vaccines and biopharmaceuticals. Its Blood Testing is dedicated to preventing the spread of infectious diseases through the development and sale of blood-screening assays and equipment that protect the world's blood supply. Its vaccines segment offers approximately 20 influenza, meningococcal, travel, and pediatric and other vaccines. The biopharmaceuticals segment researches, develops, manufactures and markets a range of therapeutic products for cancer and infectious and pulmonary disease.

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
  
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
  
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
  
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
  
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
  
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
  
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
  
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
  
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
  
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
  
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
  
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
  
Wound Management
The Wound Management Subsector includes therapeutics that treat cuts, abrasions, and burns from trauma or diseases.
Medical Devices
Clinical Diagnostics
The Clinical Diagnostics Subsector includes medical devices that analyze human body specimens within a medical setting. These devices, including equipment, biological and chemical reagents are primarily used for the diagnosis of diseases.
Transfusion Medicine
The Transfusion Medicine Subsector includes medical devices and accessories that prepare or implement blood transfusion.
  
Outsourced Services  
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
  
Drug Discovery Services
The Drug Discovery Services Subsector includes companies that provide biopharmaceutical companies with novel biological targets and drug leads.
  
Scientific Products  
Analytical Instruments
The Analytical Instruments Subsector includes scientific products that determine the quantitative and qualitative nature of biochemical samples.
  
Bioanalytical Instruments
The Bioanalytical Instruments Subsector includes scientific products, devices and apparatuses that determine the quantitative and qualitative nature of a biological samples.
  
Consumables
The Consumables Subsector includes chemicals, reagents, standards, media, and disposable labware that are normally depleted or worn out by continuous use.
  
General Laboratory Equipment
The General Laboratory Equipment Subsector includes products that are used during routine laboratory procedures, such as sample preparation, processing, storage, cleaning, and purification.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for treatment of allergic reactions in early stages of clinical research where human subject is involved.

Buyer Products:

  • Xolair (Omalizumab)
  
Upper Respiratory  
Monoclonal Antibodies
Therapeutics that treat allergic reactions by specifically binding and inhibiting inflammatory substances.

Buyer Products:

  • Xolair (Omalizumab)
  
Cardiovascular System  
Heart Disorders  
Angina  
Calcium Channel Blocking Agents
Therapeutics that treat chest pains by preventing the entry of calcium into heart muscle cells.

Buyer Products:

  • Cardene (Nicardipine Hydrochloride)
  
Heart Failure (HF)  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat the ineffective pumping of the heart by blocking beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Dilatrend (Carvedilol)
  
Complications  
Edema  
Loop Diuretic Agents
Therapeutics that treat the excessive accumulation of fluids by increasing the excretion of sodium, potassium, chloride ions, and water in urine.

Buyer Products:

  • Bumex (Bumetanide)
  • Demadex (Torsemide)
  
Myocardial Infarction (MI)  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat irreversible damage to the heart muscle by blocking the beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Dilatrend (Carvedilol)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • R639/SPP301 (Endothelin Receptor A Antagonist)
  • TF Fab (Monoclonal Antibody Fragment)
  • BO-653 (Antioxidant)
  • AXV034343 (Endothelin A Receptor Antagonist)
  
Vascular Disorders  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Platelet Aggregation Inhibitors  
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that treat/prevent thrombosis by selectively inhibiting the binding of adenosine diphosphate (ADP) to its platelet receptor, thereby inhibiting platelet aggregation.

Buyer Products:

  • Ticlid (Ticlopidine Hydrochloride)
  
Hypertension  
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.

Buyer Products:

  • Cardene (Nicardipine Hydrochloride)
  • Cardene SR (Nicardipine Hydrochloride)
  
Loop Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium, chloride ions, and water in urine.

Buyer Products:

  • Demadex (Torsemide)
  
Stroke  
Anticoagulating Agents (Anticoagulants)  
Platelet Aggregation Inhibitors  
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that prevent or treat damage to nerve cells of the brain by preventing platelets from clumping together.

Buyer Products:

  • Ticlid (Ticlopidine Hydrochloride)
  
Dermatology
Acne  
Vulgaris  
Retinoids/Vitamin A Analogs
Therapeutics that treat acne by helping in cell differentiation as well as prevent cell proliferation.

Buyer Products:

  • Roaccutane/Accutane (Isotretinoin)
  
Lesion/Scaling Disorders  
Psoriasis  
Monoclonal Antibodies
Therapeutics that treat psoriasis by binding to certain receptors on antigens associated with the disease, thus modulating the immune reaction.

Buyer Products:

  • Raptiva (Efalizumab)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • BAL2299 (Nuclear Receptor Modulator)
  • BAL4079 (9-Cis Retinoic Acid)
  • BCX-4208 (Second-Generation PNP Inhibitor)
  
Ulcers  
Diabetic Foot  
Platelet Derived Growth Factors (PDGF)
Therapeutics that treat foot ulcers by promoting the recruitment of cells involved in tissue repair and also enhancing the formation of granulation tissue.

Target Products:

  • Regranex (Beclapermin)
  
Digestive System  
Gastrointestinal Tract Disorders  
Gastroesophageal Disorders  
Nausea/Vomiting  
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.

Buyer Products:

  • Kytril (Granisetron Hydrochloride)
  
Liver Disorders  
Cirrhosis  
Complications  
Edema  
Loop Diuretic Agents
Therapeutics that prevent edema by excretion of sodium, potassium, chloride ions, and water in urine.

Buyer Products:

  • Bumex (Bumetanide)
  • Demadex (Torsemide)
  
Hepatitis  
Hepatitis B  
Chronic  
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.

Buyer Products:

  • Pegasys (Pegylated Interferon Alfa-2a)
  
Hepatitis C  
Chronic  
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.

Buyer Products:

  • Pegasys (Pegylated Interferon Alfa-2a)
  • Roferon-A (Interferon Alfa-2a, Recombinant)
  
Interferons/Nucleoside Analogs
Therapeutics that treat viral infections by preventing viral replication, stimulating the immune system to also fight the virus, and inhibits replication of viral DNA by incorporating themselves into growing viral DNA stands.

Buyer Products:

  • Pegasys/Copegus (Pegylated Interferon Alfa-2a/Ribavirin)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • R1124 (GPCR Modulator)
  • R1479 (Polymerase Inhibitor)
  • R440 (Cell Cycle Inhibitor)
  • R1270 (Levovirin)
  • GM -611 (Motilin Agonist)
  • R1518 (Levovirin)
  • R1068 (GPCR Modulator)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • R1626 (Polymerase Inhibitor)
  • R1541 (Integrin Antagonist)
  
Endocrinology/Metabolism  
Diabetes  
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes  
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Products that sensitizes organs to insulin.

Buyer Products:

  • R483 (Insulin Sensitizer)
  
Intermediary Metabolism Disorders  
Gout  
Gouty Arthritis  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation preventing cyclooxygenase activity.

Buyer Products:

  • Naprosyn/EC-Naprosyn/Anaprox/Anaprox DS (Naproxen)
  
Parathyroid Gland Disorders  
Hyperparathyroidism (HPT)  
Vitamin D Analogs
Therapeutics that act similar to Vitamin D.

Buyer Products:

  • Rocaltrol (Calcitriol)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • R1439 (Nuclear Receptor Modulator)
  • R1438 (Enzyme Inhibitor)
  • BIM 51077 (GLP-1 Analogue)
  • R1440 (Enzyme Modulator)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • R1499 (Enzyme Inhibitor)
  • R1498 (Nuclear Receptor Modulator)
  • Glucokinase Enzyme
  • R1593 (Nuclear Receptor Modulator)
  
Hematology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • R1516
  • CERA (Continuous Erythropoietin Receptor Activator)
  
Red Blood Cell (RBC) Disorders  
Anemia  
Recombinant Human Erythropoietins
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues by stimulating red blood cell production.

Buyer Products:

  • NeoRecormon (Epoetin Beta)
  • CERA (Continuous Erythropoietin Receptor Activator)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • R1593 (Nuclear Receptor Modulator)
  
Serum Factor Disorders  
Hypocalcemia  
Vitamin D Analogs
Therapeutics that treat hypocalcemia by increasing serum levels of calcium, as well as helping the bone calcification process.

Buyer Products:

  • Rocaltrol (Calcitriol)
  
Immunology
Autoimmune Disorders
Arthritis  
Rheumatoid Arthritis (RA)  
Immunotherapy  
Monoclonal Antibodies
Therapeutics that treat rheumatoid arthritis by interfering with specific immune pathways implicated in the progression of the disease.

Buyer Products:

  • Rituxan (Rituximab)
  • R1569/MRA (Tocilizumab)
  
Multiple Sclerosis (MS)  
Interferons
Therapeutics that treat multiple sclerosis with a recombinant human protein that downregulates the antibody response of the immune system.

Target Products:

  • Betaseron (Interferon Beta-1b)
  
Psoriasis  
Monoclonal Antibodies
Therapeutics that treat psoriasis by binding to certain receptors on antigens associated with the disease, thus modulating the immune reaction.

Buyer Products:

  • Raptiva (Efalizumab)
  
Immune Deficiency Disorders  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Fusion Inhibitors
Therapeutics that manage HIV by inhibiting the fusion of the HIV into human host cells where it can replicate.

Buyer Products:

  • Fuzeon (Enfuvirtide)
  
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.

Buyer Products:

  • Fortovase (Saquinivir)
  • Invirase (Saquinavir Mesylate)
  
Reverse Transcriptase Inhibitors (Nucleoside Analogs)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Hivid (Zalcitabine)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • BAL2299 (Nuclear Receptor Modulator)
  • Fortovase (Saquinivir)
  • R1487 (Kinase Inhibitor)
  • R1295 (Integrin Antagonist)
  • R724/T-1249 (Fusion Inhibitor)
  • Raptiva (Efalizumab)
  • BCX-4208 (Second-Generation PNP Inhibitor)
  • R1599
  • R1594 (Anti-CD20 Molecule )
  • R1503 (Kinase Inhibitor)
  • R944 (Protease Inhibitor)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • BCX-4208 (Second-Generation PNP Inhibitor)
  • R1628
  • R1541 (Integrin Antagonist)
  • R1495 (Non-Nucleoside Reverse Transcriptase Inhibitor)
  • CLIP (Class II Associated Invariant Chain Peptide)
  • BR3-FC
  
Infectious Diseases
Bacterial
Antibacterial Agents
Broad Spectrum  
Antibiotics  
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.

Buyer Products:

  • Rocephin (Ceftriaxone Sodium)
  
Sulfonamides
Therapeutics that treat a wide variety of bacterial infections by inhibiting folic acid synthesis.

Buyer Products:

  • Gantrisin (Sulfisoxazole)
  
Narrow Spectrum
Digestive System  
Shigellosis  
Diaminopyrimidines/Sulfonamides
Therapeutics that treat an infection of the intestines caused by Shigella by inhibiting folic acid synthesis.

Buyer Products:

  • Bactrim (Trimethoprim/Sulfamethoxazole)
  
Otolaryngology (Ear/Nose/Throat)  
Otitis Media  
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the middle ear inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.

Buyer Products:

  • Bactrim (Trimethoprim/Sulfamethoxazole)
  
Respiratory System
Bronchitis  
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections leading to inflammation of the bronchi in the lungs by inhibiting certain enzymes that are vital for bacterial DNA transcription and repair.

Buyer Products:

  • Bactrim (Trimethoprim/Sulfamethoxazole)
  
Cystic Fibrosis/Pseudomonas Aeruginosa  
Aminoglycosides
Therapeutics that treat a generalized genetic disorder characterized by excess mucous production in the lungs that leads to severe respiratory infection by inhibiting bacterial protein synthesis.

Target Products:

  • TOBI (Tobramycin)
  • (Tobi) Inhalable Tobramycin
  
Pneumonia  
Tissue Factor Pathway Inhibitor (TFPI)
Therapeutics that treat pneumonia by blocking a key step in blood coagulation.

Target Products:

  • Tifacogin
  
Urology  
Urinary Tract Infections (UTI)  
Antibacterial Agents (Antibiotics)  
Diaminopyrimidines/Sulfonamides
Therapeutics that treat bacterial infections of the urinary tract by inhibiting dihydrofolate reductase resulting in decreased bacterial nucleic acid/protein production.

Buyer Products:

  • Bactrim (Trimethoprim/Sulfamethoxazole)
  
Mycological (Fungal)  
Antifungal Agents  
Narrow Spectrum  
Respiratory System  
Pneumocystis Carinii Pneumonia (PCP)  
Dihydrofolate Reductase Inhibitors/Dihydropteroate Synthetase Inhibitors
Therapeutics that treat infections of the lungs of immunocompromised patients caused by Pneumocystis carinii by interfering with folic acid synthesis and growth of organism.

Buyer Products:

  • Bactrim (Trimethoprim/Sulfamethoxazole)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.

Buyer Products:

  • BAL5788 (Antibiotic)
  • BAL8557 (Antifungal Agent)
  • R1270 (Levovirin)
  • R1479 (Polymerase Inhibitor)
  • CS-023 (Prenteral Crbapenem)
  • R1558
  • R1461 (Fusion Protein)
  • R1518 (Levovirin)
  • Fortovase (Saquinivir)
  • R724/T-1249 (Fusion Inhibitor)
  • R944 (Protease Inhibitor)

Target Products:

  • Multivalent (ACYW) Meningococcal Vaccine
  • PA-824
  • HIV Vaccine
  • Meningococcus B Vaccine
  • Flu Cell Culture Vaccine
  • Hepatitis C (HCV) Vaccine
Protozoal  
Antiprotozoal Agents  
Narrow Spectrum  
Malaria  
Aminoquinolines
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by inhibiting parasite growth.

Buyer Products:

  • Lariam (Mefloquine Hydrochloride)
  
Diaminopyrimidines/Sulfonamides
Therapeutics that treat infections due to parasites by inhibiting folic acid synthesis and also blocking the action of the dihydrofolate enzyme.

Buyer Products:

  • Fansidar (Sulfadoxine/Pyrimethamine)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.

Buyer Products:

  • BAL8349 (Antifungal Agent)
  • R1626 (Polymerase Inhibitor)
  • R1495 (Non-Nucleoside Reverse Transcriptase Inhibitor)
  • Tamiflu (Oseltamivir)

Target Products:

  • H9N2 Avian Influenza Vaccine
Viral
DNA Viruses  
Hepadnavirus  
Hepatitis B  
Chronic  
Interferons
Therapeutics that treat viral infections characterized by inflammation of the liver for more than six months with natural proteins that have antiviral activity.

Buyer Products:

  • Pegasys (Pegylated Interferon Alfa-2a)
  
Herpesvirus  
Cytomegalovirus (CMV)  
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.

Buyer Products:

  • Valcyte (Valganciclovir Hydrochloride)
  
RNA Viruses  
Flavivirus  
Hepatitis C  
Chronic  
Interferons
Therapeutics that treat hepatitis by providing a naturally occurring protein that stimulates the immune system.

Buyer Products:

  • Pegasys (Pegylated Interferon Alfa-2a)
  • Roferon-A (Interferon Alfa-2a, Recombinant)
  
Interferons/Nucleoside Analogs
Therapeutics that treat viral infections characterized by long term inflammation of the liver by enhancing the immune system and by inhibiting replication of viral DNA.

Buyer Products:

  • Pegasys/Copegus (Pegylated Interferon Alfa-2a/Ribavirin)
  
Orthomyxovirus  
Influenza A  
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza A virus by preventing the release of new viruses from infected cells.

Buyer Products:

  • Tamiflu (Oseltamivir)
  
Influenza B  
Neuraminidase Inhibitors
Therapeutics that treat viral infections of the respiratory tract caused by Influenza B virus by preventing the release of new viruses from infected cells.

Buyer Products:

  • Tamiflu (Oseltamivir)
  
Retrovirus  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Fusion Inhibitors
Therapeutics that manage HIV by inhibiting the fusion of the HIV into human host cells where it can replicate.

Buyer Products:

  • Fuzeon (Enfuvirtide)
  
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.

Buyer Products:

  • Fortovase (Saquinivir)
  • Invirase (Saquinavir Mesylate)
  
Reverse Transcriptase Inhibitors (Nucleoside Analogs)
Therapeutics that help manage HIV by inhibiting the action of reverse transcriptase, an enzyme necessary for the DNA synthesis on a RNA template.

Buyer Products:

  • Hivid (Zalcitabine)
  
Vaccines  
Viral  
Single Target  
Influenza (Flu)
Therapeutics that prevent or treat viral infections of the respiratory tract by producing or artificially increasing immunity to the Influenza virus.

Target Products:

  • Fluvirin (Triple Antigen Flu Vaccine)
  
Rabies
Therapeutics that prevent or treat viral infections that infect brain cells by producing or artificially increasing immunity to the rabies virus.

Target Products:

  • RabAvert (Rabies Vaccine)
  
Musculoskeletal System  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • R1164
  • R1487 (Kinase Inhibitor)
  • R1599
  • R1594 (Anti-CD20 Molecule )
  • ED-71 (Vitamin D Derivative)
  • CHS 13340 (Recombinant Parathyroid Hormone)
  • R1503 (Kinase Inhibitor)
  • Rituxan (Rituximab)
  • Raptiva (Efalizumab)
  • R1295 (Integrin Antagonist)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • BR3-FC
  • R1628
  
Skeletal Disorders  
Bone Disorders  
Osteoporosis  
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts.

Buyer Products:

  • Boniva (Ibandronate Biphosphonate)
  
Selective Estrogen Receptor Modulators (SERM)
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts while not stimulating the endometrial lining of the uterus.

Buyer Products:

  • Evista (Raloxifene Hydrochloride)
  
Joint Disorders  
Ankylosing Spondylitis  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.

Buyer Products:

  • Naprosyn/EC-Naprosyn/Anaprox/Anaprox DS (Naproxen)
  
Gouty Arthritis  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by inhibiting cyclooxygenase activity.

Buyer Products:

  • Naprosyn/EC-Naprosyn/Anaprox/Anaprox DS (Naproxen)
  
Osteoarthritis (OA)  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.

Buyer Products:

  • Naprosyn/EC-Naprosyn/Anaprox/Anaprox DS (Naproxen)
  
Rheumatoid Arthritis (RA)  
Analgesics  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.

Buyer Products:

  • Naprosyn/EC-Naprosyn/Anaprox/Anaprox DS (Naproxen)
  
Immunotherapy  
Monoclonal Antibodies
Therapeutics that treat rheumatoid arthritis by interfering with specific immune pathways implicated in the progression of the disease.

Buyer Products:

  • Rituxan (Rituximab)
  • R1569/MRA (Tocilizumab)
  
Neurology
Neurological Disorders  
Epilepsy  
Primary Generalized Seizures  
Absence (Petit Mal)  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Klonopin (Clonazepam)
  
Monotherapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Klonopin (Clonazepam)
  
Akinetic Pattern  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Klonopin (Clonazepam)
  
Monotherapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Klonopin (Clonazepam)
  
Myoclonic  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevent nerve activation.

Buyer Products:

  • Klonopin (Clonazepam)
  
Monotherapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Klonopin (Clonazepam)
  
Neuromuscular Disorders  
Multiple Sclerosis (MS)  
Interferons
Therapeutics that treat multiple sclerosis with a recombinant human protein that down regulates the antibody response of the immune system.

Target Products:

  • Betaseron (Interferon Beta-1b)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • R1500 (Enzyme Inhibitor)
  • R1485 (GPCR Modulator)
  • MT 500 (GPCR Modulator)
  • Rituxan (Rituximab)
  • R673 (GPCR Modulator)
  • R1204 (GPCR Modulator)
  
Psychiatric Disorders  
Anxiety  
Generalized Anxiety Disorder (GAD)  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.

Buyer Products:

  • Valium (Diazepam)
  
Panic Disorder  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat panic disorder by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.

Buyer Products:

  • Klonopin (Clonazepam)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • R1067 (GPCR Modulator)
  • R1627 (Enzyme Inhibitor)
  • R1576 (GPCR Modulator)
  • R1577 (Enzyme Inhibitor)
  • R1497 (GPCR Modulator)
  • R1533 (Enzyme Inhibitor)
  • R1603 (GPCR Modulator)
  • R1315 (GPCR Modulator)
  
Oncology
Breast Cancer  
Localized  
Monoclonal Antibodies
Therapeutics that treat breast cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.

Buyer Products:

  • Herceptin (Trastuzumab)
  
Metastatic  
Antimetabolite Agents  
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage breast cancers that have spread beyond their original tumor site by inhibiting the production of DNA.

Buyer Products:

  • Xeloda (Capecitabine)
  
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of breast cancer cells and inhibit the cancer cells' growth and induce their death.

Buyer Products:

  • Avastin (Bevacizumab)
  • Herceptin (Trastuzumab)
  
Dermatology
Kaposi`s Sarcoma  
Interferons
Therapeutics that treat and manage cancers of spindle cells by providing a naturally occurring protein that stimulates the immune system.

Buyer Products:

  • Roferon-A (Interferon Alfa-2a, Recombinant)
  
Malignant Melanoma  
Interleukins  
Interleukin-2 (IL-2)
Therapeutics that treat and manage skin cancers that have spread beyond their original tumor site by providing a naturally occurring protein that stimulates the immune system.

Target Products:

  • Proleukin (Aldesleukin)
  
Digestive System  
Colon Cancer/Colorectal Cancer  
Metastatic  
Antimetabolite Agents  
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage colorectal tumors that have spread beyond their original tumor site by inhibiting the production of DNA.

Buyer Products:

  • Xeloda (Capecitabine)
  
Monoclonal Antibodies
Therapeutics that treat colorectal cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.

Buyer Products:

  • Avastin (Bevacizumab)
  
Pancreatic Cancer  
Metastatic  
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage cancers of the pancreas by blocking the action of tyrosine kinase enzyme through switching off the signals from the epidermal growth factor receptors, which promote cell growth.

Buyer Products:

  • Tarceva (Erlotinib)
  
Hematology  
Leukemia  
Lymphoid  
Chronic  
Hairy Cell  
Interferons
A recombinantly produced protein normally produced by the body to fight viral infection used to treat and manage a slowly progressing cancer of lymphoid cells characterized by numerous irregular cytoplasmic projections.

Buyer Products:

  • Roferon-A (Interferon Alfa-2a, Recombinant)
  
Lymphocytic (CLL)  
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of leukemia cells and thereby induce their death.

Buyer Products:

  • Rituxan (Rituximab)
  
Myeloid  
Acute  
Promyelocytic (APL)  
Retinoids/Vitamin A Analogs
Therapeutics that treat acute promyelocytic leukemia by helping in cell differentiation as well as decreasing proliferation of cells.

Buyer Products:

  • Vesanoid (Tretinoin)
  
Chronic  
Myelogenous (CML)  
Interferons
Therapeutics that treat and manage slowly progressing cancers of myelogenous cells by providing a naturally occurring protein that stimulates the immune system.

Buyer Products:

  • Roferon-A (Interferon Alfa-2a, Recombinant)
  
Lymphoma  
Non-Hodgkin`s Lymphoma (NHL)  
Monoclonal Antibodies
Therapeutics that bind to specific receptors on the surface of lymphoma cells and thereby induce their death.

Buyer Products:

  • Rituxan (Rituximab)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Buyer Products:

  • Avastin (Bevacizumab)
  • R1273 (Monoclonal Antibody)
  • Diflomotecan (Topoisomerase Inhibitor I)
  • Therafab
  • R1564/DMXAA (Vascular Targeting Agent)
  • R1550 (Monoclonal Antibody)
  • E2F Activating Compound
  • R1594 (Anti-CD20 Molecule )
  • R1668 (E2F Modulator)
  • G-024856 (Hedgehog Antagonist)
  • AS1404
  • CAL (Anti-PTHrP Monoclonal Antibody)
  • CHC 12103 (Polyglutamate TXL)
  • AHM (Anti-HM 1.24 Monoclonal Antibody)
  • R1536 (Enzyme Inhibitor)
  • R1492 (Enzyme Inhibitor)
  • KOS-862 (Epothilone D)
  • Therex
  • Pemtumomab/R1549
  • Tarceva (Erlotinib)
  • PRO64553 (Anti-CD40 Antibody)

Target Products:

  • CHIR-12.12 (Anti-CD40)
  • CHIR-258
  • CHIR-265
  • Proleukin (Aldesleukin)
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.

Buyer Products:

  • R1453 (Enzyme Inhibitor)
  • R1645 (Enzyme Inhibitor)
  • R1630 (Enzyme Inhibitor)
  • R547 (Enzyme Inhibitor)
  • 2H7
  • R1559 (Enzyme Inhibitor)
  • R1454 (Enzyme Inhibitor)
  • BN80927 (Topoisomerase I/II Inhibitor)
  • R1491 (Angiogenesis Inhibitor)
  • Trastuzumab-DM1
  • P53 Pathway Activators
  • PRO1762
  
Respiratory System/Thoracic  
Lung Cancer  
Non Small Cell Lung Cancer (NSCLC)  
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by blocking the tyrosine kinase enzyme by switching off the signals from the epidermal growth factor receptors.

Buyer Products:

  • Tarceva (Erlotinib)
  
Monoclonal Antibodies
Therapeutics that treat lung cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.

Buyer Products:

  • Avastin (Bevacizumab)
  
Urology
Kidney Cancer (Renal Cell Carcinoma)
Metastatic
Interleukins  
Interleukin-2 (IL-2)
Therapeutics that treat and manage renal cancers that have spread beyond their original tumor site by providing a naturally occurring protein that stimulates the immune system.

Target Products:

  • Proleukin (Aldesleukin)
  
Monoclonal Antibodies
Therapeutics that treat kidney cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.

Buyer Products:

  • Avastin (Bevacizumab)
  
Ovarian Cancer  
Adenocarcinoma  
Monoclonal Antibodies
Therapeutics that treat ovarian cancer by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.

Buyer Products:

  • Pemtumomab/R1549
  
Ophthalmology  
Degenerative Disorders  
Macular Degeneration (AMD)  
Vascular Endothelial Growth Factor Inhibitors (VEGF)
Therapeutics that treat macular degeneration by binding to the vascular endothelial growth factor (VEGF) and inhibiting the formation of blood vessels in the eye.

Buyer Products:

  • Lucentis (Ranibizumab)
  
Retinitis  
AIDS-Related Cytomegalovirus (CMV) Retinitis  
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.

Buyer Products:

  • Cytovene (Ganciclovir)
  • Valcyte (Valganciclovir Hydrochloride)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Lucentis (Ranibizumab)
  
Pain Management  
Anesthesia  
General (Systemic)  
Adjunctive  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that result in anesthesia by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.

Buyer Products:

  • Versed (Midazolam)
  
Reversal  
Gamma-Aminobutyric Acid (GABA) Receptor Antagonists
Therapeutics that reverse general anesthesia by competitively inhibiting benzodiapizines at the GABA receptors, thus reducing their effect and reversing the anesthesia.

Buyer Products:

  • Romazicon (Flumazenil)
  
Non-Narcotics  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.

Buyer Products:

  • Aleve (Naproxen Sodium)
  • Toradol (Ketorolac Tromethamine)
  • Naprosyn/EC-Naprosyn/Anaprox/Anaprox DS (Naproxen)
  
Non-Steroidal Anti-Inflammatory Drugs (NSAID) Combinations  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Decongestants
Therapeutic combinations that produce insensibility or numbness through the inhibition of prostoglandins while also preventing nasal decongestion.

Buyer Products:

  • Aleve Cold & Sinus (Naproxen/Pseudoephedrine)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.

Buyer Products:

  • Bondronat (Ibandronate)
  
Respiratory System
Lower Respiratory Tract Disorders (Lung Disorders)
Asthma  
Prophylactic Treatments  
Monoclonal Antibodies
Therapeutics that treat asthma with monoclonal antibodies.

Buyer Products:

  • Xolair (Omalizumab)
  
Cystic Fibrosis (CF)  
Complications  
Bacterial Infections  
Antibacterial Agents (Antibiotics)  
Aminoglycosides
Therapeutics that treat bacterial infections of the lung resulting as a complication of cystic fibrosis by interfering with RNA, thus leading to inhibition of protein synthesis.

Target Products:

  • TOBI (Tobramycin)
  • (Tobi) Inhalable Tobramycin
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • R1295 (Integrin Antagonist)
  • R667 (Nuclear Receptor)
  • Zenapax (Daclizumab)
  • R448
  • R411 (Integrin Antagonist)

Target Products:

  • TOBI (Tobramycin)
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • R1456 (Nuclear Receptor)
  
Surgery  
Cardiovascular System  
Complications  
Peripheral Arterial Occlusion  
Thrombolytic Agents
Therapeutics that treat diseases of the blood vessels outside the heart by dissolving blood clots.

Buyer Products:

  • Cathflo Activase (Alteplase)
  
Toxicology  
Substance Abuse  
Withdrawal  
Alcohol  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.

Buyer Products:

  • Valium (Diazepam)
  
Transplantation
Bone Marrow  
Complications  
Cytomegalovirus (CMV) Infections  
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.

Buyer Products:

  • Cytovene (Ganciclovir)
  
Heart  
Complications  
Cytomegalovirus (CMV) Infections  
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.

Buyer Products:

  • Cytovene (Ganciclovir)
  • Valcyte (Valganciclovir Hydrochloride)
  
Rejection Prophylaxis  
Immunosuppressants
Therapeutics that help manage and suppress the response of the immune system to foreign tissue.

Buyer Products:

  • CellCept (Mycophenolate Mofetil)
  
Hepatic (Liver)  
Complications  
Cytomegalovirus (CMV) Infections  
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.

Buyer Products:

  • Cytovene (Ganciclovir)
  • Valcyte (Valganciclovir Hydrochloride)
  
Rejection Prophylaxis  
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.

Buyer Products:

  • CellCept (Mycophenolate Mofetil)
  
Lung
Complications  
Cytomegalovirus (CMV) Infections  
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.

Buyer Products:

  • Cytovene (Ganciclovir)
  • Valcyte (Valganciclovir Hydrochloride)
  
Rejection Prophylaxis  
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.

Target Products:

  • Pulminiq (Aerosolized Cyclosporine)
  
Pancreas  
Complications  
Cytomegalovirus (CMV) Infections  
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.

Buyer Products:

  • Cytovene (Ganciclovir)
  • Valcyte (Valganciclovir Hydrochloride)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the management of rejection and infection in early stages of clinical research where human subject is involved.

Buyer Products:

  • R1524 (Calcineurin Inhibitor)
  • Raptiva (Efalizumab)
  • VAL (Liver Regenerator)
  • ISATX247 Trans
  • BCX-4208 (Second-Generation PNP Inhibitor)
  
Renal (Kidney)  
Complications  
Cytomegalovirus (CMV) Infections  
Viral DNA Polymerase Inhibitors
Therapeutics that treat cytomegalovirus (CMV) infections by inhibiting a key enzyme necessary for viral replication.

Buyer Products:

  • Cytovene (Ganciclovir)
  • Valcyte (Valganciclovir Hydrochloride)
  
Rejection Prophylaxis  
Immunosuppressants
Therapeutics that manage and suppress the response of the immune system to foreign tissue.

Buyer Products:

  • CellCept (Mycophenolate Mofetil)
  
Monoclonal Antibodies
Protein-based therapeutics that target specific substances like proteins.

Buyer Products:

  • Zenapax (Daclizumab)
  
Urology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • R450 (GPCR Modulator)
  • CERA (Continuous Erythropoietin Receptor Activator)
  • R1484 (GPCR Modulator)
  • R701 (GPCR Antagonist)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • R1437 (GPCR Antagonist)
  • R873 (GPCR Agonist)
  • R1554 (GPCR Antagonist)
  
Urological Disorders  
Kidney (Renal)  
Chronic Renal Failure (CRF)  
Complications  
Anemia  
Recombinant Human Erythropoietins
Therapeutics that treat the condition resulting from the scarcity of red blood cells by inducing the production of red blood cells.

Buyer Products:

  • CERA (Continuous Erythropoietin Receptor Activator)
  
Edema  
Loop Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissues by promoting the excretion of urine.

Buyer Products:

  • Bumex (Bumetanide)
  • Demadex (Torsemide)
  
Weight Management  
Obesity  
Lipase Inhibitors
Therapeutics that reduce the absorption of fat by inhibiting production of lipase, which is an enzyme that helps breaking down fat in the food.

Buyer Products:

  • Xenical (Orlistat)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • R1065 (GPCR Modulator)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • R1496 (GPCR Modulator)
  
Wound Management
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of wounds in very early stages of research where no human subject is involved.

Buyer Products:

  • Vascular Endothelial Growth Factor
  
Ulcers  
Diabetic Foot  
Platelet Derived Growth Factors (PDGF)
Therapeutics that treat foot ulcers by promoting the recruitment of cells involved in tissue repair and also enhancing the formation of granulation tissue.

Target Products:

  • Regranex (Beclapermin)
  
Medical Devices
Clinical Diagnostics
Chemistry  
Analyzers  
Blood Gas
Analyzers used to measure blood gases for diagnostic purposes.

Buyer Products:

  • Roche Diagnostics AVL Compact 1-3
  • Roche Diagnostics AVL 988 Series
  • Roche Diagnostics OMNI Series
  
Discrete  
Limited Assay
Discrete analyzers with limited test menu.

Buyer Products:

  • Roche Diagnostics AVL 9180 Series
  • Roche Diagnostics OMNI Series
  
Multiple Assay
Multi-System analyzers designed for high throughput generally used in high volume clinical laboratories.

Buyer Products:

  • Roche Diagnostics Reflotron Series
  • Roche Diagnostics Cobas Integra Series
  • Roche Diagnostics Roche/Hitachi 902/912
  
Home Testing  
Cholesterol
Home test kits which test for cholesterol levels in patient blood.

Buyer Products:

  • Roche Diagnostics Accu-Chek Plus
  • Roche Diagnostics Accutrend System
  
Glucose  
Invasive
Devices that generally use blood samples for testing and require a needlestick or pin-prick.

Buyer Products:

  • Roche Diagnostics Accu-Chek Active Meter
  • Roche Diagnostics Accu-Chek Advantage/Advantage II/Sensor Meter
  • Roche Diagnostics Accu-Chek Compact Meter
  • Roche Diagnostics Accu-Chek Plus
  • Roche Diagnostics Accu-Chek Simplicity
  • Roche Diagnostics Accu-Chek Aviva
  • Roche Diagnostics Accu-Chek Instant DM
  • Roche Diagnostics Accu-Chek Complete/Sensor Complete Meter
  
Test Strips
Specific glucose test devices used with glucose monitors.

Buyer Products:

  • Roche Diagnostics Accu-Chek Advantage Test Strips
  • Roche Diagnostics Accu-Chek Go
  • Roche Diagnostics Accu-Chek Compact Test Drums
  • Roche Diagnostics Accu-Chek Simplicity Test Strips
  • Roche Diagnostics Accu-Chek Comfort Curve/Sensor Comfort/Advantage Comfort/Advantage II Test Strips
  • Roche Diagnostics Glucotrend Strips
  • Roche Diagnostics Accu-Chek Active Test Strips
  
Point of Care Testing  
Critical Care Analysis  
Analyzers
Chemistry analyzers which may be used for the chemical analysis of body fluids and designed for use at the bedside during the course of patient care.

Buyer Products:

  • Roche Diagnostics Elecsys 1010
  • Roche Diagnostics Elecsys 2010
  
Test Cartridges
Specific analyte test devices used in conjunction with critical care chemistry analyzers.

Buyer Products:

  • Roche Diagnostics Elecsys 1010
  • Roche Diagnostics Elecsys 2010
  
Glucose Monitoring  
Invasive  
Continuous Analysis
Glucose test devices which measure patient glucose levels on a continual basis.

Buyer Products:

  • GlucOnline Microdialysis System
  
Random Analysis
Glucose test devices which measure patient glucose levels as a blood sample is obtained.

Buyer Products:

  • Roche Diagnostics AccuData GTS/AccuData HDM
  • Roche Diagnostics Accu-Chek Inform System
  
Kits  
Cardiac
Test kits used to aid in the diagnosis of heart conditions.

Buyer Products:

  • Roche Diagnostics Cardiac D-Dimer
  
Reagents  
Calibrators  
Routine Analyte  
Multiple
Calibrators which contain multiple specific analytes used to establish the accuracy of chemistry analyzers.

Buyer Products:

  • Roche Diagnostics Cobas Integra Reagents Series
  
Single
Calibrators which contain a specific analyte used to establish the accuracy of chemistry analyzers.

Buyer Products:

  • Roche Diagnostics Cobas Integra Reagents Series
  
Controls  
Routine
Controls used to test the accuracy of discrete chemistry test systems.

Buyer Products:

  • Roche Diagnostics Cobas Integra Reagents Series
  
Test Kits  
Pharmacogenetic
Test kits designed to determine individuals' reaction to specific medications based on their specific genes.

Buyer Products:

  • Roche Diagnostics AmpliChip CYP450 Test
  
Hemostasis/Coagulation  
Analyzers  
Automated
Automated coagulation analyzers.

Buyer Products:

  • Roche Diagnostics Stago Sta Compact
  • Roche Diagnostics Stago Sta R
  
Reagents  
Test Kits  
Prothrombin Time
Reagents used to perform prothrombin time assays.

Buyer Products:

  • Roche Diagnostics CoaguChek Series
  
Immunoassays
Analyzers  
Autoimmune
Analyzers used to perform autoimmune testing.

Buyer Products:

  • Roche Diagnostics COBAS AMPLICOR Analyser
  • Roche Diagnostics COBAS AmpliPrep System
  
Multiple Assay
Immunoassay analyzer designed to perform multiple assays over multiple modalities.

Buyer Products:

  • Roche Diagnostics Cobas Core II
  • Roche Diagnostics Elecsys 2010
  • Roche Diagnostics E170
  • Roche Diagnostics Elecsys 1010
  
Reagents
Calibrators  
Therapeutic Drugs
Calibrators used in the measurement of therapeutic drugs.

Buyer Products:

  • Roche Diagnostics Cobas Integra Reagents Series
  
Toxicology/Abuse Drugs
Calibrators used in the measurement of drugs of abuse.

Buyer Products:

  • Roche Diagnostics Cobas Integra Reagents Series
  
Controls  
Therapeutic Drugs
Controls which contain known concentrations of specific therapeutic drugs used to verify the performance of therapeutic drug testing systems.

Buyer Products:

  • Roche Diagnostics Cobas Integra Reagents Series
  
Test Kits
Bacterial  
Chlamydia
Immunoassay kits which test for current or previous infection caused by the Chlamydia organism.

Buyer Products:

  • Roche Diagnostics COBAS AMPLICOR CT/NG Test/AMPLICOR CT/NG Test
  
Tuberculosis
Immunoassay test kits which quantitatively measure tuberculosis antibody in plasma or serum.

Buyer Products:

  • Roche Diagnostics Amplicor M. tuberculosis Test
  
Radioimmunoassays  
Cancer Marker
Radioimmunoassay test kits which measure for cancer markers in plasma or serum.

Buyer Products:

  • Roche Diagnostics Cobas Core Reagent Series
  
Cardiac
Radioimmunoassay test kits which measure for analytes associated with heart disease in plasma or serum.

Buyer Products:

  • NT-proBNP
  
Special/Immuno Chemistry
Cancer Marker  
Breast
Diagnostic assay used to detect specific breast tumor or cancer markers.

Buyer Products:

  • BCM 18 (Breast Cancer Marker)
  
Colorectal (Colon)
Diagnostic assay used to detect specific colorectal (colon) tumor or cancer markers.

Buyer Products:

  • Roche Diagnostics hemo FEC
  
Cardiac  
Myocardial Infarction/Heart Failure  
Myoglobin
Immunoassay test kits which quantitatively measure for myoglobin in plasma or serum.

Buyer Products:

  • Roche Diagnostics Cardiac Reader
  
Troponin
Immunoassay test kits which quantitatively measure for troponin in plasma or serum.

Buyer Products:

  • Roche Diagnostics Cardiac Reader
  • Roche Diagnostics TROPT Sensitive
  
Creutzfeldt-Jakob Disease (Mad Cow Disease)
Immunoassay test kits which help diagnose Creutzfeldt-Jakob Disease (Mad Cow Disease).

Target Products:

  • vCJD Immunoassay Kit
  
Therapeutic Drugs
Immunoassay test kits which quantitatively measure for therapeutic drugs in serum or urine using automated instrumentation..

Buyer Products:

  • Roche Diagnostics Cobas Integra Reagents Series
  
Toxicology/Abuse Drugs  
Multiple Drug Kit
Immunoassay test kits which measure for more than one drug of abuse in body fluids.

Buyer Products:

  • Roche Diagnostics OnTrak TesTcard 9
  • Roche Diagnostics Cobas Integra Reagents Series
  
Viral
HTLV I/II/III
Immunoassay kit which tests for the presence of infectious disease or previous infection caused by the HTLV I, II and III viruses.

Target Products:

  • HTLV-III ELISA
  • HTLV-I/II ELISA
  
Hepatitis
Immunoassay kits which tests for current or previous infection caused by Hepatitis viruses.

Target Products:

  • HBsAg System 3 ELISA
  • HCV 3.0 ELISA
  • HBCore ELISA
  • HCV Ag ELISA 2.0
  • HBsAg System 2 ELISA
  • Anti HBS ECi
  • RIBA HCV 3.0 SIA
  • Anti HCV ECi
  • HBsAg ECi
  
Human Immunodeficiency Virus (HIV)
Serum
EIA
Immunoassay kit which tests for the presence of infectious disease caused by the Human Immunodeficiency Virus in serum or plasma using EIA methodologies.

Target Products:

  • HIV-1/2 ELISA
  • RIBA HIV-1/HIV-2 SIA
  
Genotyping
Tests that "fingerprint" HIV according to chromosomal makeup in order to track specific strains.

Buyer Products:

  • Roche Diagnostics AMPLICOR HIV-1 Monitor Test
  • Roche Diagnostics Amplicor HIV-1 Test
  • Roche Diagnostics COBAS Amplicor HIV-1 Test
  
Microbiology
Genetic Probes/PCR
Automated Analyzers
Analyzers designed for genetic probe assays.

Target Products:

  • Procleix Optiva System
  • Procleix System
  • Procleix Tigris System
  
Reagents
Bacterial  
Tuberculosis
Genetic probe for detection and/or quantitation of Mycobacterium tuberculosis.

Buyer Products:

  • Roche Diagnostics COBAS AMPLICOR Mycobacterium avium Test/AMPLICOR MAV Test
  • Roche Diagnostics COBAS AMPLICOR MTB Test/AMPLICOR MTB Test
  • Roche Diagnostics COBAS AMPLICOR Mycobacterium Intracellular (MIN) Test/AMPLICOR MIN Test
  
Viral
Cytomegalovirus
Genetic probe for detection and/or quantitation of Cytomegalovirus.

Buyer Products:

  • Roche Diagnostics AMPLICOR CMV Test
  • Roche Diagnostics COBAS AMPLICOR CMV Monitor Test
  
Hepatitis B Virus
Genetic probes for detection and/or quantitation of HBV.

Buyer Products:

  • Roche Diagnostics AMPLINAT MPX Test
  • Roche Diagnostics COBAS AmpliScreen HBV Test

Target Products:

  • Procleix Ultrio Assay
Hepatitis C Virus
Genetic probes for detection and/or quantitation of HCV.

Buyer Products:

  • Roche Diagnostics COBAS AMPLICOR HCV Monitor Test/AMPLICOR HCV Monitor Test
  • Roche Diagnostics COBAS AMPLICOR HCV Test/AMPLICOR HCV Test
  • Roche Diagnostics COBAS AmpliScreen HCV Test
  • Roche Diagnostics AMPLINAT MPX Test

Target Products:

  • Procleix HIV-1/HCV Assay
  • Procleix Ultrio Assay
Human Immunodeficiency Virus (HIV)
Genetic probes for detection and quantification of HIV.

Buyer Products:

  • Roche Diagnostics AMPLINAT MPX Test
  • Roche Diagnostics Amplicor HIV-1 Test
  • Roche Diagnostics COBAS AmpliScreen HIV-1 Test

Target Products:

  • Procleix HIV-1/HCV Assay
  • Procleix Ultrio Assay
Human Papilloma Virus
Genetic probes for the detection of HPV.

Buyer Products:

  • Roche Diagnostics Digene Hybrid Capture II HPV Test
  
West Nile Virus
Genetic probe for detection and/or quantitation of West Nile Virus.

Buyer Products:

  • Roche Diagnostic TaqScreen West Nile Virus Test

Target Products:

  • Procleix West Nile Virus Assay
Specimen Collection  
Blood  
Capillary  
Lancets
Sharps type of device used to puncture the skin in order to collect a capillary blood sample.

Buyer Products:

  • Roche Diagnostics SoftTouch Lancets
  • Roche Diagnostics Accu-Chek Autoclix Lancing System
  • Roche Diagnostics Safe-T-Pro Lancets
  • Roche Diagnostics Softclix Pro Lancets
  
Urinalysis  
Analyzers  
Chemistry
Analyzers used to perform chemical analysis of urine.

Buyer Products:

  • Roche Diagnostics Miditron Junior II
  • Roche Diagnostics Miditron M
  • Roche Diagnostics Urisys 2400
  • Roche Diagnostics Urisys 1100
  
Reagents  
Test Strips
Reagents, in a embedded strip format, used to perform chemical, and physical analysis of urine or body fluids.

Buyer Products:

  • Roche Diagnostics Chemstrip Series
  
Transfusion Medicine  
Immunohematology  
Blood Conversion System
Devices that convert blood group A or B to O to facilitate transfusion procedures.

Target Products:

  • A-ECO Blood System
  
Outsourced Services  
Development/Manufacturing Services  
Contract Manufacturing Organizations (CMO)  
Pharmaceuticals  
Biologics
Active Ingredient Contract Manufacturing Organizations (CMO) that manufacture antibodies, proteins, and genetic materials.

Target Products:

  • Contract Manufacturing Services
  
Drug Discovery Services  
Target Discovery/Validation  
Services
Drug discovery services that discover and validate drug targets for the development of novel biopharmaceutical drugs.

Target Products:

  • Sagres Discovery Oncogenome
  
Scientific Products  
Analytical Instruments  
Analyzers  
Gas Monitors  
Multiple Component  
Benchtop
Multi-component gas monitors that are generally located on the counter top.

Buyer Products:

  • Roche Diagnostics AVL OMNI 1-9
  
Bioanalytical Instruments  
Biomolecular  
Microplate Readers  
Systems  
Multiple Parameter
Microplate reader systems that used a combination of fluorescent, luminescent, and/or photoemission detectors.

Buyer Products:

  • Roche Diagnostics Lumi-Imager
  
Sequencers  
Automated  
Nucleic Acid
Automated gel electrophoresis or capillary electrophoresis sequencers used to analyze nucleic acid sample.

Buyer Products:

  • Genome Sequencer 20
  
Synthesizers  
Peptides
Synthesizer systems used for the identification and synthesis of peptide samples.

Buyer Products:

  • Roche Diagnostics Rapid Translation System
  
Thermal Cyclers  
Accessories
Supplementary products used to enhance the performance of a thermal cycler.

Buyer Products:

  • Roche Diagnostics MagNA Pure LC
  
Systems
Thermal cycler components assembled as a single unit.

Buyer Products:

  • Roche Diagnostics LightCycler
  
Consumables  
Bioanalytical Chemistry  
Molecular Biology  
Microarray Technology  
Microarray Chips
Microarray/biochip components that give detailed analysis of differential expression in normal and diseased or treated cells.

Buyer Products:

  • Roche Diagnostics AmpliChip CYP 450
  
Nucleic Acid Analysis  
Kits  
Nucleic Acid  
Transfection
Nucleic acid analysis kits that are used for the introduction of DNA into a recipient eukaryote cell and its subsequent integration into the recipient cells chromosomal DNA

Buyer Products:

  • Roche Diagnostics FuGENE
  
General Laboratory Equipment  
Automation Equipment  
Robotic Instruments  
Workstations
Robotic instrument systems that transfer liquid and gas samples and also heat and cool samples.

Buyer Products:

  • Roche Diagnostics Task Targeted Automation
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Pfizer Inc. n/a 180,093.387 22.38 12.19 3.51 3.48 12.80
GlaxoSmithKline plc (ADR) n/a 152,087.937 18.72 17.97 4.05 4.03 27.09
sanofi-aventis (ADR) n/a 127,939.289 n/a 13.23 4.40 3.65 5.96
Merck & Co., Inc. n/a 74,228.204 16.16 14.38 3.37 3.57 4.55
Abbott Laboratories n/a 63,852.982 19.09 16.40 2.86 2.90 14.33
Wyeth n/a 62,226.960 16.96 15.25 3.32 3.09 7.90
Eli Lilly & Co. n/a 60,194.193 30.36 17.02 4.11 3.86 5.58
Bristol Myers Squibb Co. n/a 47,206.437 15.74 20.03 2.46 2.46 10.57
Bayer AG (ADR) n/a 29,666.486 15.67 n/a 0.91 0.95 7.23
Schering-Plough Corp. n/a 27,219.124 148.76 34.04 2.86 2.72 3.99
Celgene Corporation n/a 13,095.053 237.30 99.89 24.39 16.51 25.93
MedImmune, Inc. n/a 8,851.607 n/a 91.18 7.12 6.47 7.10
Digene Corporation n/a 813.463 409.40 55.52 6.14 5.50 5.49
Idenix Pharmaceuticals, Inc. n/a 622.954 n/a -9.06 9.63 5.96 3.01
Vical Incorporated n/a 159.602 n/a -6.27 13.30 10.01 2.13
Hollis-Eden Pharmaceuticals Inc. n/a 140.887 n/a -5.31 34,011.97 1.25 3.62
CancerVax Corporation n/a 77.430 n/a -2.39 1.92 19.36 2.92
ViRexx Medical Corp. (USA) n/a 77.165 n/a n/a n/a n/a 20.31
Viragen, Inc. n/a 22.864 n/a n/a 57.16 n/a -4.02
Buyer
  Pfizer Inc. n/a 180,093.387 22.38 12.19 3.51 3.48 12.80
Johnson & Johnson n/a 172,344.164 16.61 15.65 3.41 3.24 6.71
Target
  Pfizer Inc. n/a 180,093.387 22.38 12.19 3.51 3.48 12.80
GlaxoSmithKline plc (ADR) n/a 152,087.937 18.72 17.97 4.05 4.03 27.09
Roche Holding Ltd. (ADR) n/a 128,694.321 28.56 28.26 4.65 4.23 7.33
sanofi-aventis (ADR) n/a 127,939.289 n/a 13.23 4.40 3.65 5.96

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  sanofi-aventis (ADR) n/a 127,939.289 n/a 13.23 4.40 3.65 5.96
Crucell N.V. (ADR) n/a 1,063.780 n/a n/a 23.09 20.76 6.43
Genelabs Technologies n/a 20.973 n/a n/a 2.35 n/a 4.61
Buyer
  Memory Pharmaceuticals Corp. 100.00% 86.845 n/a -2.91 7.81 8.56 4.15
Emisphere Technologies Inc. 82.80% 188.949 n/a -8.21 53.39 94.47 -11.16
deCODE genetics, Inc. 30.00% 446.679 n/a -6.03 10.16 11.13 -24.54
Vernalis plc (ADR) 3.20% 218.152 n/a n/a 7.75 n/a -20.50
sanofi-aventis (ADR) n/a 127,939.289 n/a 13.23 4.40 3.65 5.96
Genentech, Inc. n/a 86,076.342 67.37 45.63 12.98 9.88 15.42
SAP AG (ADR) n/a 68,589.425 37.95 30.67 6.72 5.84 11.41
Target
  International Business Machines Corp. n/a 128,488.325 16.37 14.13 1.41 1.41 5.84
sanofi-aventis (ADR) n/a 127,939.289 n/a 13.23 4.40 3.65 5.96
Novartis AG (ADR) n/a 115,962.020 22.25 18.00 3.57 3.25 3.52
Amgen, Inc. n/a 82,623.807 22.71 19.41 6.65 5.80 13.30
Baxter International Inc. n/a 24,024.789 24.91 17.89 2.44 2.32 10.66
Schering AG (ADR) n/a 19,731.499 26.52 24.44 3.09 n/a 6.39
Gen-Probe Incorporated n/a 2,718.419 45.10 51.86 8.88 8.11 6.67
Cubist Pharmaceuticals n/a 1,119.137 n/a -230.00 9.28 5.39 -80.62
Crucell N.V. (ADR) n/a 1,063.780 n/a n/a 23.09 20.76 6.43
Sirna Therapeutics, Inc. n/a 447.674 n/a -24.70 91.43 24.87 11.30
Phase Forward Incorporated n/a 384.718 109.91 39.21 4.42 3.81 10.08
Active Power, Inc. n/a 254.037 n/a n/a 14.28 n/a 4.69
Insightful Corporation n/a 34.117 17.21 n/a 1.53 n/a 3.94
Genelabs Technologies n/a 20.973 n/a n/a 2.35 n/a 4.61
Boehringer Ingelheim GmbH n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Gen-Probe Incorporated n/a 2,718.419 45.10 51.86 8.88 8.11 6.67
Buyer
  Laboratory Corp. of America n/a 7,118.293 18.49 18.27 2.14 2.00 -30.03
Applied Biosystems Group, Applera Corp n/a 5,028.973 26.00 23.06 2.75 2.70 4.17
PDL BioPharma Inc. n/a 3,396.917 n/a 70.83 12.15 7.90 47.83
Gen-Probe Incorporated n/a 2,718.419 45.10 51.86 8.88 8.11 6.67
MDS Inc. (USA) n/a 2,702.970 55.69 n/a 2.10 n/a 3.41
IDEXX Laboratories, Inc. n/a 2,596.716 33.54 33.37 4.07 3.69 10.38
Aspreva Pharmaceuticals Corporation n/a 957.444 79.13 14.87 12.52 5.37 6.47
Grupo Casa Saba, S.A. (ADR) n/a 575.960 8.11 n/a 0.28 n/a 1.33
Target
  Schering AG (ADR) 10.60% 19,731.499 26.52 24.44 3.09 n/a 6.39
Johnson & Johnson n/a 172,344.164 16.61 15.65 3.41 3.24 6.71
GlaxoSmithKline plc (ADR) n/a 152,087.937 18.72 17.97 4.05 4.03 27.09
sanofi-aventis (ADR) n/a 127,939.289 n/a 13.23 4.40 3.65 5.96
Merck & Co., Inc. n/a 74,228.204 16.16 14.38 3.37 3.57 4.55
Abbott Laboratories n/a 63,852.982 19.09 16.40 2.86 2.90 14.33
Medco Health Solutions Inc. n/a 17,090.882 26.76 21.37 0.45 0.40 -97.33
Henry Schein, Inc. n/a 4,054.789 26.77 21.80 0.87 0.78 8.46
Gen-Probe Incorporated n/a 2,718.419 45.10 51.86 8.88 8.11 6.67
PSS World Medical, Inc. n/a 1,231.781 29.34 28.05 0.77 0.76 6.85
Cubist Pharmaceuticals n/a 1,119.137 n/a -230.00 9.28 5.39 -80.62
Nabi Biopharmaceuticals n/a 344.009 n/a -12.57 3.18 2.70 4.12
National Health Service (United Kingdom) n/a n/a n/a n/a n/a n/a n/a
The American Red Cross n/a n/a n/a n/a n/a n/a n/a
Government of New Zealand n/a n/a n/a n/a n/a n/a n/a
United Nations n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  GlaxoSmithKline plc (ADR) n/a 152,087.937 18.72 17.97 4.05 4.03 27.09
Novartis AG (ADR) n/a 115,962.020 22.25 18.00 3.57 3.25 3.52
Amgen, Inc. n/a 82,623.807 22.71 19.41 6.65 5.80 13.30
Bayer AG (ADR) n/a 29,666.486 15.67 n/a 0.91 0.95 7.23
Gilead Sciences, Inc. n/a 28,422.599 34.59 29.68 14.01 11.28 9.39
Novo Nordisk A/S (ADR) n/a 20,193.337 21.79 21.81 3.74 n/a 4.65
Dade Behring Holdings, Inc. n/a 2,922.525 23.86 21.95 1.76 1.69 8.04
Gen-Probe Incorporated n/a 2,718.419 45.10 51.86 8.88 8.11 6.67
Nektar Therapeutics n/a 1,871.131 n/a -16.29 14.82 11.15 7.96
Crucell N.V. (ADR) n/a 1,063.780 n/a n/a 23.09 20.76 6.43
ISIS Pharmaceuticals, Inc. n/a 562.764 n/a -8.72 14.02 12.07 -14.11
Biomira Inc. (USA) n/a 114.418 n/a n/a 30.55 n/a 6.70
Genelabs Technologies n/a 20.973 n/a n/a 2.35 n/a 4.61
Buyer
  GlaxoSmithKline plc (ADR) n/a 152,087.937 18.72 17.97 4.05 4.03 27.09
Novartis AG (ADR) n/a 115,962.020 22.25 18.00 3.57 3.25 3.52
Target
  Pfizer Inc. n/a 180,093.387 22.38 12.19 3.51 3.48 12.80
Johnson & Johnson n/a 172,344.164 16.61 15.65 3.41 3.24 6.71
GlaxoSmithKline plc (ADR) n/a 152,087.937 18.72 17.97 4.05 4.03 27.09
Roche Holding Ltd. (ADR) n/a 128,694.321 28.56 28.26 4.65 4.23 7.33
International Business Machines Corp. n/a 128,488.325 16.37 14.13 1.41 1.41 5.84
sanofi-aventis (ADR) n/a 127,939.289 n/a 13.23 4.40 3.65 5.96
Novartis AG (ADR) n/a 115,962.020 22.25 18.00 3.57 3.25 3.52
Amgen, Inc. n/a 82,623.807 22.71 19.41 6.65 5.80 13.30
Merck & Co., Inc. n/a 74,228.204 16.16 14.38 3.37 3.57 4.55
Abbott Laboratories n/a 63,852.982 19.09 16.40 2.86 2.90 14.33

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 27,655.5 1,888.3 29,543.8
Other Revenue 0.0 31.4 31.4
Total Revenue 27,655.5 1,919.7 29,575.1
Cost of Revenue 7,245.8 732.1 7,977.9
SG&A Expense 9,277.7 501.2 9,778.9
Depreciation & Amortization 787.4 66.2 853.6
Research & Development 4,443.0 433.9 4,876.9
Interest Expense 0.0 0.0 0.0
Other Operating Expense -1,126.9 20.5 -1,106.4
Unusual Expense (Income) 277.2 15.7 292.9
Total Expenses 20,904.2 1,769.6 22,673.7
Operating Income 6,751.3 150.1 6,901.4
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 231.3 -30.6 200.7
Gain/Loss On Sale Of Assets 0.0 -0.3 -0.3
Other, Net 0.0 83.7 83.7
Income Before Taxes 6,982.6 202.9 7,185.5
Income Taxes 1,732.0 22.4 1,754.4
Income After Taxes 5,250.6 180.5 5,431.0
Minority Interest (IS) -734.4 0.0 -734.4
Net Income - Excl. Xord. Items 4,516.2 180.5 4,696.6
Discontinued Operations -9.3 0.0 -9.3
Net Income - Incl. Xord. Items 4,506.8 180.5 4,687.3
Income Avail. to Common 4,506.8 180.5 4,687.3
Share Items
Basic Avg. Shares Outstanding 1,690.0 190.7 1,880.7
Basic EPS - Excl. Xord. Items 5.34 0.95 2.50
Basic EPS - Incl. Xord. Items 2.67 0.95 2.49
Full Dilution Adjustment 0.0 1.5 1.5
Fully Diluted Shares Outstanding 1,720.0 205.0 1,925.0
F.D. EPS - Excl. Xord. Items 2.63 0.90 2.44
F.D. EPS - Incl. Xord. Items 2.62 0.90 2.43
Dividends Per Common Share 0.97 0.00 0.97
Balance Sheet
Assets
Cash and Equivalents 3,292.7 291.4 3,584.1
ST Investments 12,972.2 400.4 13,372.6
Accounts Receivable 5,995.1 483.2 6,478.3
Inventory 3,925.9 231.7 4,157.5
Other Current Assets 1,559.1 185.1 1,744.2
Current Assets 27,745.0 1,591.9 29,336.9
PPE 0.0 1,517.9 1,517.9
Accum D&A 0.0 -629.0 -629.0
PPE, Net 11,757.3 888.8 12,646.1
Goodwill & Intangibles 9,647.6 1,365.7 11,013.3
Long Term Investments 1,750.7 780.2 2,530.9
Note Receivable 0.0 7.1 7.1
Other Assets 0.0 0.0 0.0
Other LT Assets 3,119.8 113.8 3,233.6
Total Assets 54,020.5 4,747.5 58,768.0
Liabilities
Accounts Payable 1,848.1 117.9 1,965.9
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 3,992.8 93.9 4,086.8
ST Debt 0.0 0.0 0.0
Curr Port of LTD & Cap Lease Oblg 271.0 49.6 320.6
Other (Current) Liabilities 1,280.3 303.4 1,583.7
Current Liab. 7,392.2 564.8 7,957.0
LT Debt 7,259.8 890.9 8,150.8
Capitalized Lease Obligations 0.0 156.7 156.7
Total LT Debt 7,259.8 1,047.6 8,307.4
Minority Interest (BS) 5,312.1 10.8 5,322.9
Deferred Taxes 2,739.8 0.0 2,739.8
Other LT Liab. 4,119.8 140.2 4,260.0
Total Liabilities 26,823.7 1,763.3 28,587.1
Shareholders Equity
Common Stock 124.6 2.0 126.6
Additional Paid in Capital 0.0 2,850.5 2,850.5
Retained Earnings 29,786.2 104.1 29,890.3
Treasure Stock -2,714.1 -88.4 -2,802.5
Other Equity 0.0 115.9 115.9
Total Equity 27,196.8 2,984.1 30,180.9
Total Liab. & Equity 54,020.5 4,747.5 58,768.0
Shares Outstanding 1,725.1 198.6 1,923.7
Cash Flow
Operating Cash Flow
CF Net Income 0.0 0.0 0.0
CF Depreciation 0.0 0.0 0.0
CF Deferred Taxes 0.0 0.0 0.0
Other Non-Cash Items -411.2 0.0 -411.2
Change in Working Capital 5,142.3 192.0 5,334.3
Total Cash From Operating Activities 4,731.1 192.0 4,923.1
Investing Cash Flow
Capital Expenditures -1,464.9 -151.5 -1,616.4
Other Investing Cash Flows -2,600.4 -293.5 -2,893.8
Total Cash From Investing Activities -4,065.3 -445.0 -4,510.3
Financing Cash Flow
Dividends Paid -1,393.2 0.0 -1,393.2
Purchase Or Sale of Stock -1,575.5 363.0 -1,212.5
Purchase and Retirement of Debt -735.2 1.8 -733.4
Other Financing Cash Flow 1,221.1 0.0 1,221.1
Total Cash From Financing Activities -72.4 363.8 291.3
Exchange Rate Effects -68.5 -18.1 -86.6
Net Change in Cash 524.9 92.7 617.6
Cash Taxes Paid 603.6 74.4 677.9
Cash Interest Paid 151.1 29.2 180.2